Abivax (ABVX) Fundamental Analysis: Revenue, Earnings & Valuation

3.91 / 10

Netural

Fundamental health is poor, scoring 3.9/10. Revenue‑MV and Profit‑MV rank positively, yet Asset‑MV and Income‑tax/Profit are weak, dragging the score. Overall financial metrics suggest guarded expectations.

Analysis Checks(8/10)

Revenue-MV

Value-5.51

Score2/3

Weight20.82%

1M Return8.05%

Inventory turnover ratio

Value47.57

Score3/3

Weight18.02%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.82%

1M Return1.67%

Profit-MV

Value0.41

Score2/3

Weight16.94%

1M Return6.36%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight0.42%

1M Return0.21%

Current assets turnover ratio

Value1.78

Score2/3

Weight3.89%

1M Return1.91%

Fixed assets turnover ratio

Value7899.90

Score3/3

Weight3.59%

1M Return1.76%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight8.95%

1M Return4.08%

Asset-MV

Value-0.48

Score0/3

Weight6.95%

1M Return2.73%

Cash-MV

Value-0.09

Score2/3

Weight16.60%

1M Return6.19%

Is ABVX fundamentally strong?

ABVX scores 3.91/10 on fundamentals and holds a Fair valuation at present. Backed by its -135.58% ROE, -7354.53% net margin, -21.98 P/E ratio, 16.23 P/B ratio, and -95.58% earnings growth, these metrics solidify its Netural investment rating.